Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
AIP is calculated as log10(triglycerides/HDL-C) using molar concentrations. It reflects the balance between atherogenic and protective lipoprotein patterns and is associated with cardiovascular risk in multiple observational studies.
Formula: AIP = log10((TG [mmol/L]) / (HDL-C [mmol/L]))
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Collect fasting blood samples (8-12 hours fasting) and measure fasting triglycerides and HDL cholesterol. If values are reported in mg/dL (US convention), they must be converted to mmol/L for AIP calculation: divide triglycerides mg/dL by 88.57 to get mmol/L; divide HDL mg/dL by 38.67 to get mmol/L. Most published AIP cutoffs are based on mmol/L values.
Apply the formula: AIP = log10 (base-10 logarithm) of (TG mmol/L divided by HDL-C mmol/L). Example: TG = 150 mg/dL = 1.69 mmol/L; HDL = 45 mg/dL = 1.16 mmol/L: AIP = log10(1.69/1.16) = log10(1.46) = 0.16. Note: log10 (base-10 logarithm) is used in AIP, not the natural log (ln) used in TyG index.
AIP <0 = low atherogenic risk (favorable lipid profile). AIP 0 to 0.1 = borderline atherogenic risk. AIP >0.1 = elevated atherogenic risk. AIP >0.21 = threshold most associated with significantly increased cardiovascular events in published studies. These thresholds are derived from observational data and vary across studies — AIP is a supplementary marker, not a primary treatment decision threshold in current guidelines.
Cardiologists, preventive medicine physicians, primary care physicians
AIP captures the atherogenic dyslipidemia pattern (high TG + low HDL) that is missed by standard LDL-C measurement. It provides supplementary cardiovascular risk information particularly valuable in patients with metabolic syndrome, T2DM, or obesity where LDL may be normal despite high residual cardiovascular risk.
Endocrinologists, primary care physicians
Atherogenic dyslipidemia — high triglycerides combined with low HDL — is a defining feature of metabolic syndrome and insulin resistance. AIP directly quantifies this pattern on a single logarithmic scale, enabling easy tracking of atherogenic dyslipidemia improvement with lifestyle changes or pharmacotherapy.
Gynecologists, endocrinologists
PCOS is associated with atherogenic dyslipidemia even in normal-weight women. AIP can quantify the lipid atherogenicity in PCOS patients and track improvement with weight loss, combined oral contraceptives, or metformin therapy.
Cardiologists, preventive medicine specialists
Patients on statin therapy who achieve LDL goals but have persistently high TG and low HDL may have elevated AIP despite normal or near-normal LDL-C. AIP identifies this residual lipid risk pattern, which may benefit from additional interventions such as fibrates, high-dose omega-3 fatty acids, or SGLT2 inhibitors.
Cardiovascular researchers, lipidologists
AIP is widely used in observational research examining the association between lipid phenotypes and cardiovascular outcomes in populations with metabolic syndrome, diabetes, and insulin resistance. It complements apoB and LDL particle size measurements as a non-traditional lipid risk marker.
The classic atherogenic dyslipidemia pattern — elevated triglycerides (>150 mg/dL) combined with low HDL-C (<40 mg/dL in men, <50 mg/dL in women) — is common in insulin resistance, T2DM, obesity, and metabolic syndrome. This pattern produces high AIP and is associated with small dense LDL particles, which are more atherogenic than large buoyant LDL. Standard LDL-C can appear normal even when AIP is elevated, underestimating true cardiovascular risk.
Triglycerides typically increase by 50-300 mg/dL above fasting baseline after meals, particularly after carbohydrate-rich or fatty meals. A non-fasting TG will significantly inflate AIP, producing a falsely elevated atherogenic index. Always confirm at least 8-12 hours of fasting before accepting the lipid panel for AIP calculation.
All published AIP cutoffs (low risk <0, borderline 0-0.1, high risk >0.1-0.21) are based on mmol/L values. Using mg/dL values in the AIP formula without converting produces a completely different numerical result that cannot be interpreted against published thresholds. Convert: TG mmol/L = TG mg/dL ÷ 88.57; HDL mmol/L = HDL mg/dL ÷ 38.67.
AIP responds well to metabolic lifestyle interventions: carbohydrate restriction and Mediterranean diet reduce TG and raise HDL, improving AIP. Regular aerobic exercise raises HDL and reduces TG. Weight loss of 5-10% body weight substantially lowers TG and improves AIP. These lifestyle changes target the insulin resistance underlying atherogenic dyslipidemia.
Fibrates (fenofibrate, gemfibrozil) reduce TG by 30-50% and raise HDL by 10-15%, substantially lowering AIP. High-dose prescription omega-3 fatty acids (icosapent ethyl at 4g/day — REDUCE-IT trial) reduce TG by ~50% and have proven cardiovascular event reduction in patients with high TG. Both agents are specifically indicated for atherogenic dyslipidemia AIP phenotype.
Statins are the cornerstone of LDL-C reduction but have modest effects on TG (10-30% reduction) and HDL (5-10% increase). A patient may achieve LDL goal on statin therapy while AIP remains elevated due to persistent high TG and low HDL. This residual risk pattern may benefit from add-on fibrates or omega-3 fatty acids, particularly when TG >200 mg/dL despite statin therapy.
SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 receptor agonists (semaglutide, liraglutide) both reduce TG and improve the lipid profile beyond glucose lowering. These agents are particularly beneficial in T2DM patients with elevated AIP (high TG, low HDL pattern), and their cardiovascular benefits in T2DM may partly operate through lipid and metabolic improvements.
Several studies have shown that elevated AIP correlates with subclinical atherosclerosis as measured by coronary artery calcium (CAC) score progression over time. AIP may identify patients at risk of CAC progression who appear low-risk by standard lipid assessment, supporting its role as an adjunctive marker in intermediate-risk cardiovascular prevention decisions.
AIP is not a recommended primary treatment target in ACC/AHA or ESC lipid management guidelines. LDL-C, non-HDL-C, and apoB are the established primary targets. AIP provides supplementary risk information and helps identify atherogenic dyslipidemia phenotype for additional intervention. Do not use AIP alone to initiate or escalate lipid-lowering therapy — it should complement, not replace, standard lipid management.
AIP proposed by Dobiasova and Frohlich (Clin Biochem 2001). AMORIS study validation (Walldius et al., JAMA 2001, n=175,553): AIP >0.21 associated with significantly increased MI risk. Meta-analysis confirming AIP as independent CVD predictor: Zhong et al. (Cardiovasc Diabetol 2021, 14 studies). AIP in metabolic syndrome: Niroumand et al. (J Res Med Sci 2015). AIP in PCOS: Berneis et al. (Eur J Endocrinol 2009). AIP and CAC: Quispe et al. (J Clin Lipidol 2020). Units must be mmol/L for all published cutoffs.
AIP summarizes the triglyceride-to-HDL relationship on a logarithmic scale. Higher values suggest a more atherogenic lipid phenotype and may indicate increased residual cardiovascular risk.
Use AIP as an adjunctive lipid-risk marker in patients with mixed dyslipidemia, metabolic syndrome traits, or discordant traditional lipid markers.
AIP is not currently the primary treatment target in major lipid guidelines. It should be interpreted as a supplementary marker alongside standard lipid and clinical risk metrics.
For related assessments, see Cholesterol Ratio, LDL Calculator and ASCVD Risk Calculator.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate total cholesterol/HDL ratio and triglyceride/HDL ratio from a standard lipid panel. A total/HDL ratio below 3.5 is optimal. For full cardiovascular risk assessment, use [ASCVD Risk Calculator](/tools/ascvd-risk) or [Framingham Risk Score](/tools/framingham-risk).
OpenCardiologyEnter total cholesterol, HDL, and triglycerides to calculate LDL-C via the Friedewald equation. Also calculates non-HDL and cholesterol ratios. Free, instant.
OpenCardiologyCalculate 10-year ASCVD risk using current 2026 ACC/AHA Pooled Cohort Equations. Statin thresholds: <5% low, 5–7.5% borderline, ≥7.5% intermediate, ≥20% high.
Open